Masco Group acquires KeyPlants AB, a leading global provider of modular Life Science facilities
Masco Group, global provider of technological solutions for the pharmaceutical and biotech industries, has acquired a majority stake in Swedish company KeyPlants AB. The move will strengthen Masco’s leadership in engineering technologies for life sciences.
KeyPlants is a leading international industry partner for standardized as well as customized process-integrated modular prefabricated facility solutions. Based in Stockholm, the company has a fully integrated supply chain with more than 45 years of experience in project engineering, production and delivery, and has supplied more than 3,500 high-specification modules to at least 30 countries.
This partnership will strengthen Masco Group by combining its leadership in clean utilities and process technologies with KeyPlants’ expertise and innovative energy in prefabricated, modular facility solutions. It will support stronger value propositions for global supply chain challenges such as flexibility, reliability and fast-track manufacturing timelines to a global customer base of biopharmaceutical manufacturers and CDMOs focused on biologics, pharma and advanced therapy medicinal products (ATMPs), such as cell and gene therapies.
“We are extremely happy to partner with KeyPlants, as it will expand our capabilities, service and product offerings, and evolve our manufacturing capacity,” says Luca Borella, CEO of Masco Group. “We look forward to working with them to further accelerate the global adoption of their innovative fast-track facility solutions, which are an essential aspect in the life science industry.” He adds: “The companies share similar values, notably the commitment to teamwork, sustainability and customer care. Innovation is also an important synergetic element.”
“KeyPlants’ management and team are fully committed to this partnership with Masco Group,” says Jörgen Harrysson, Managing Director and Board Member of KeyPlants AB. “Its global presence and network enables KeyPlants to continue with our strategy to serve existing and new clients with our fast-track solutions, including customized facilities as well as standardized PODs. We are also thrilled to be able to expand our presence and offerings in North America, Europe and Africa.”
“We see KeyPlants and Masco Group as a perfect fit, and we are excited at the prospect of making KeyPlants and its skilled teams an integral part of the growth trajectory of the Masco Group family,” comments Frans K. A. Maas, Masco Group Board Member. “Masco Group is part of RSBG SE, a German-based long-term industrial partner of successful medium-sized companies, pursuing a buy-and-build strategy and focusing on competences and areas which are of great importance during global transformations. This acquisition supports the vision to become a technology-leading turnkey provider, in particular in the growing and demanding markets of biologics, vaccines and ATMPs.”
About Masco Group
Masco Group is an integrated solutions provider, partner to the top tier pharmaceutical and biotechnological companies. Its companies Stilmas, Olsa, DOC and BCD are leaders in clean utilities, process technologies and services. Headquartered in Milan-Italy, Masco Group has production sites and subsidiaries in Europe, America and Asia and serves more than 6000 clients globally, delivering around 300 projects per year.
More info: Masco Group
KeyPlants, headquartered in Stockholm, Sweden, is a leader in modular off-site construction for the life science industry, having delivered 100+ projects globally. Our customers benefit from KeyPlants’ vast experience and expertise, resulting in 30-50% shorter timelines and increased predictability with regards to schedule, cost, and quality. KeyPlants delivers turnkey facilities, including process equipment, utilities, and digital solutions.
More info: KeyPlants
You can find the official statement by Masco Group on Coronavirus here.
Masco Group and Olsa have been on the front line in the fight against the pandemic, never stopping working on our products, which are essential to the pharmaceutical industry. We supplied systems for the production of therapeutics used against Covid-19, such as antivirals, vaccines and antibodies.At our facilities around the world we have put in place all suitable protection measures, both for our employees and our clients.
Since traveling is difficult, we are promoting for our clients the use of technologies such as smart glasses and virtual reality for the testing and maintenance of our systems.
Find out what trade fairs, conferences, exhibitions and events we are participating in this year and don’t miss the opportunities to get to know us and our capabilities better.
|ISPE EUROPE ANNUAL MEETING AND EXPO
30 March – 2 April 2020
31 March – 2 April 2020
7 – 13 May 2020
Sao Paulo (Brasil)
2 – 4 June 2020
1 – 3 October 2020
13 – 15 October 2020
|ISPE ANNUAL MEETING AND EXPO
1 – 4 November 2020
|Pharmtech & Ingredients
10 – 13 November 2020
New Delhi (India)
25 – 27 November 2020
Fabio Poli has been a service engineer for Olsa since 2000, traveling the world to test and start Olsa’s equipment for nearly two decades.
The newspaper L’Eco di Bergamo dedicated an article to him and his job, which took him to 59 countries and “out of office” for 250-270 days a year. The “globetrotter technician” as they called him shows a great dedication and passion for his job.
His experience shows how a company can grow with its employees.
«Still today for every assignment I have the same enthusiasm as the first day; I consider it a unique and formative work and personal experience», says Fabio.
Read the complete article here: Collaudatore globetrotter «La mia vita in viaggio»
Fabio Poli è un collaudatore Olsa dal 2000 e viaggia nel mondo per testare e avviare gli impianti Olsa da quasi vent’anni. L’Eco di Bergamo gli ha dedicato un articolo, raccontando del suo lavoro che lo ha portato in 59 paesi e che lo fa viaggiare fuori sede circa 250-270 giorni all’anno. Il “collaudatore globetrotter” come lo hanno definito dimostra ancora oggi una grande dedizione e passione per il suo lavoro.
La sua esperienza dimostra come un’azienda possa crescere con i suoi dipendenti.
«Anche oggi, ogni incarico è vissuto con lo stesso entusiasmo del primo giorno e lo considero un’esperienza lavorativa e personale unica e formativa», dice Fabio.
Qui l’articolo completo: Collaudatore globetrotter «La mia vita in viaggio»
It is with great pleasure and honor that we announce that Masco Group has signed the acquisition of a majority shareholding of BCD Engineering Ltd, active since 1983 in the engineering and manufacturing of high purity process systems worldwide for the Pharmaceutical, Biotechnology, Food & Beverage and Chemical industries. They have particular expertise in Product Formulation, Clean in Place, Clean Utilities and Thermal Treatment technologies. Based out of Charleville-Cork Ireland, BCD employs about 250 highly skilled people.
This acquisition, pending CCPC Ireland approval, will strengthen Masco Group’s leadership in both the segment for Olsa liquid process (Pharma plus Food & Beverage) technologies as well as for Stilmas clean utilities, liquid processing, super skids and turn-key manufacturing systems for the global markets.
For more on their expertise, capabilities and industries served visit www.bcd.ie
Il prossimo 21-22 novembre avrà luogo un training workshop in lingua italiana promosso da Stilmas e DOC Validation dal titolo “Pharmaceutical Water & Steam Systems: Current International Industry Practices, Technological Trends and Regulatory News”.
Che argomenti verranno trattati?
Il seminario tratterà in generale di acqua e vapore per uso farmaceutico, con una panoramica completa in base alle direttive europee (EDQM/EMA), statunitensi (FDA/USP) e cGMP internazionali (Anvisa, WHO, PIC/S, etc.) supportata dall’esperienza globale di Stilmas e DOC relativa all’ispezione degli impianti.
Gli argomenti trattati nell’ambito delle clean utilities saranno: requisiti normativi, attuali criteri di design come da GEP e nuove tendenze tecnologiche, life-cycle della validazione e manutenzione, monitoraggio e controllo dei sistemi.
Quanto sono attuali queste tematiche?
Il materiale del seminario è aggiornato ai Regulatory Requirements del 2019, in particolar modo a causa della nuova monografia EP per Acqua per Iniettabili rilasciata ad aprile 2017 e alla bozza di revisione dell’EU GMP Annex 1 (dicembre 2017).
A chi è indirizzato questo seminario?
Il workshop è indirizzato ai professionisti e manager delle Industrie Farmaceutiche coinvolti nelle applicazioni dei sistemi di produzione di acqua e vapore ad uso farmaceutico (sistemi di Qualità QA e QC, Regolamentazione e Validazione, Ingegneria, Manutenzione e Produzione (API e sistemi di dosaggio).
Per ulteriori informazioni scrivere a: firstname.lastname@example.org
Join Olsa at the 5th edition of the APIC Arab Pharmaceutical Industry Congress 2019 organized by Akhnaton Trading & Representation on 8-9 October at the Hilton Heliopolis in Cairo, Egypt.
Our experts will give lectures on Cleaning in Place (Procedures, systems and customization), super skids for sterile manufacturing and modular approach.
To register: https://bit.ly/2nbVP9A
The APIC is designed to provide an innovative and comprehensive overview of the latest developments in pharmaceutical industry. The event offers a platform for professionals to share knowledge, network, and discuss trends in the pharmaceutical industry with the pioneers in the field.
The three main streams (Scientific Lectures) will be: – Production, Bio pharmaceuticals & productivity. Quality assurance & Regulation Compliance. Research & Development.
Olsa will take part in the annual event CPhI Worldwide 2019 in Frankfurt.
Find our experts in the PMEC area, hall 11, booth 110B71.
The world’s largest pharmaceutical exhibition, CPhI Worldwide houses six zones representing each stage of the pharmaceutical supply chain – from APIs, machinery and packaging to outsourcing and biopharmaceuticals. Uniting over 45,000 visiting attendees and 2,500 international exhibitors, CPhI Worldwide is the place to network and source cost-effective pharma solutions from all over the world – in just 3 days, under one roof.
See the official Event Guide Preview.
The history of plasma fractionation began in WWII, with the need to develop blood serum products to help soldiers suffering from shock and burns.
Nowadays, Olsa is helping the fight against important diseases by designing and manufacturing plasma fractionation systems.
Check out this relevant and insightful article by Roberto Vassena, Olsa’s director of commercial operations, on the implementation of an impressive plasma fractionation system in a CIS country.
Make sure to follow our new and improved Linkedin page for Olsa’s latest news and content:
Stilmas Expands its North American Operations with the Acquisition of Mar Cor Purification’s High Purity Water Business Based in Burlington Ontario, Canada
Milan, Italy November 1, 2018/PRNewswire/ — Stilmas is pleased to announce that effective November 1, 2018 it has acquired the assets of Mar Cor Purification’s High Purity Water Business based in Burlington, Ontario, Canada. The new company will be named Stilmas Americas, and will serve the North American market, expanding the Mar Cor Purification High Purity water portfolio of products. Mar Cor Purification currently manufactures a line of water purification equipment platforms that are compliant with the current USP and EU Purified Water (PW) and Water for Injection (WFI) standards. They specialize in standard and custom engineered turn-key systems for the Pharmaceutical, Biotech, Cosmetic and Semi-Conductor markets.
The Masco Group, with its Companies Stilmas, Olsa and DOC, is a global market leader in the field of pure water technologies and systems for the pharmaceutical and cosmetic industry. The Masco Group is headquartered in Milan, Italy, with operations in France, China, Russia and USA. Stilmas manufactures state of the art Pharmaceutical Quality Water Systems that include Multiple Effect Stills, Vapor Compression Stills and Pure Steam Generators along with other standard products.
Alberto Borella – CEO Masco Group: “We have found in the High Purity Business Line of Mar Cor Purification the perfect complement of products and competencies to successfully carry out our vision and grow our business. Stilmas Americas will become the reference clean media provider in North America”.
Benjamin Roczniak – President Stilmas Americas: “We are excited that we now have a complete portfolio of State of the Art Biopharma water products that will allow us to provide our customers with complex turnkey solutions”.
Stilmas Americas will be the hub for selling, engineering, manufacturing and servicing Stilmas equipment in North America, becoming a unique player to offer a complete range of pure media technologies in the North American market.
For further information, visit Stilmas website at www.stilmas.com.
Masco-Group has retained Industrial Investment Company of
RAG-Foundation as long-term majority shareholder
The Masco Group with its business units Stilmas, Olsa and DOC is a global market leader in the field of pure water technologies and systems for the pharmaceutical and cosmetic industry.
Masco Group has a unique track record and experience of more than 100 years in Pure Water Systems as well as complete solutions for liquid production pharmaceutical plants, including product preparation areas. Moreover, the group offers a wide range of services related to the validation in the pharmaceutical and cosmetic industry. The company has the honor to be a reliable and innovative business partner for the leading global and local pharmaceutical and cosmetic companies.
Taking into account the excellent growth opportunities regarding regional expansion, automation solutions as well as larger turnkey projects including balance of plant systems the ownership family has decided to team up with an experienced business partner enabling Masco not only to keep the traditional values of the company and their independence but also to combine it with the highly interesting knowledge and competencies of a global industrial network.
“We are excited to announce this strategic collaboration with RAG Investment Company which will support the acceleration of our business on the global scale. Our new strategic investor will allow Masco to maintain the entrepreneurial spirit and ensure that our business model, network of customers, partnerships and objectives are even reinforced to achieve new ambitious targets,” said Alberto Borella, CEO Masco Group.
Jürgen Wild the Managing Partner of RAG Investment Company:
“Masco Group is a flagship of northern Italy’s high tech industry which started very early in time to become a global player serving customers around the world. Their innovation spirit was always looking for best-in-class solutions satisfying the highest standards of its superb customer base. In addition, the company also developed forward its offering to customers from products to turnkey solutions. With the unique combination of in-house development, production, validation and service Masco Group is the recognized market leader. We are privileged to become the business partner of choice and will commit ourselves to the future success of this outstanding company.”
The Borella family maintains committed to Masco as shareholder and as board members in the management of the group.
Dr.Eng. Alberto BORELLA
CEO Masco Group
Masco Group is pleased to invite you to our Seminar, organized in collaboration with Melapack Kft. Process division dedicated to the Pharmaceutical and Cosmetic Industries.
Through the several lectures presented, it will be provided an update about the latest regulatory requirements and an anticipation about the ones that will become effective starting from 2017.
Moreover the latest technological trends related to the manufacturing of pharmaceutical and cosmetic finished products like sterile solutions, suspension and ointments will be shown through specific case studies coming from our experience.
The last part of the Seminar will be dedicated to the Quality matter and it will cover the qualification and validation aspects of material, equipment and containers in contact with the pharmaceutical drug formulation.
Entry is free, however places are limited, please register in advance to confirm your attendance.
For any additional information regarding the participation please fill the form below